Dementia is associated with iron-deficiency anemia in females: A population-based study

Chung, Shiu-Dong; Sheu, Jau Jiuan; Lin, Herng Ching; Kang, Jiunn Horng

doi:10.1016/j.jns.2014.07.062

Cited by 25 publications

(30 citation statements)

References 32 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are generally consistent with the findings of previous studies [14-16, 18, 26]. A casecontrol study indicated that women with dementia had a higher prevalence of prior IDA, compared to controls [18]. A hospital-based case-control study with 100 cases and 100 controls showed a relationship between IDA and depressive disorder; and the severity of symptoms of depressive disorder increased with the degree of IDA [15].…”

Section: Discussionsupporting

confidence: 92%

“…There is growing evidence that IDA is associated with psychosocial consequences, including adverse psychomotor function, reduced work capacity [12], delayed socioemotional development [13], and psychiatric morbidity, including anxiety disorders [14], depression [15], bipolar disorders [14], sleep disorders [16], restless legs syndrome (RLS) [17] and dementia [18]. However, some studies have concluded that there is no association between IDA and psychotic disorders.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

Lee

Chao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: It has been shown that iron deficiency anemia (IDA) is associated with psychosocial consequences and psychiatric morbidity. However, the association between adults with IDA and psychiatric disorders has not been clarified. The purpose of this study was to investigate the psychiatric disorder morbidity of an IDA group in comparison with a non-IDA group and to examine the risk of psychiatric disorders in IDA patients treated with iron supplementation. Methods: All study subjects were 20 years of age or over with newly diagnosed IDA enrolled in the Taiwan National Health Insurance Database from 2000 to 2012. We matched IDA and non-IDA subjects according to age and gender in a 1:2 ratio. Our primary outcome was diagnosis of psychiatric disorders and the patients were monitored until the end of 2013. A multivariate Cox proportional hazards regression model was used to explore the risk of psychiatric disorders in patients with IDA after adjustment for confounders, including demographic characteristics and comorbidities. Results: The adjusted hazard ratios (aHRs) of psychiatric disorders was 1.49 (95% CI = 1.43–1.56) in the IDA group compared with the non-IDA group. Among the different types of psychiatric disorders, the IDA group was associated with significantly higher incidence and risks of dementia, anxiety disorders, depression, sleep disorders, and psychotic disorders ( p < 0.05). Furthermore, iron supplementation in IDA subjects was associated with a significantly lower risk of psychiatric disorders compared to non-iron supplementation in IDA patients. Conclusions: Our study indicates that IDA subjects had an increased risk of psychiatric disorders, regardless of other confounders. In IDA patients, iron supplementation was associated with a decreased risk of psychiatric disorders. Moreover, IDA patients receiving iron supplementation also had a lower risk of sleep disorders.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

Lee

Chao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…282 Thus, iron deficiency may partially account for hypometabolism in AD since women with iron deficiency anemia have a higher prevalence of dementia. 283 Interestingly, iron deficiency and iron accumulation in AD seem paradoxical. One potential explanation is that tau differentially regulates the motor proteins dynein and kinesin; specifically, tau may preferentially inhibit kinesin, which transports cargo toward the cell periphery.…”

Section: Metal Ion Hypothesismentioning

confidence: 99%

History and progress of hypotheses and clinical trials for Alzheimer’s disease

Xie

Meng

et al. 2019

Sig Transduct Target Ther

461

350

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients. There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis. However, the ultimate etiology of AD remains obscure. In this review, we discuss the main hypotheses of AD and related clinical trials. Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD. The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD. We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.

show abstract

“…The newest reported association of ID is with sensorineural hearing loss (SNHL). Reported with IDA, the mechanism is unknown, but, in animal models, sudden SNHL is the result of cochlear defects, possibly ischemic in nature (Chung et al , ; Schieffer et al , ,b).…”

Section: Adverse Effects Of Iron Depletionmentioning

confidence: 99%

How do we manage iron deficiency after blood donation?

Kiss

Vassallo

2018

Br J Haematol

View full text Add to dashboard Cite

Blood donors and the RBCs and other components they willingly provide are essential in the delivery of healthcare in all parts of the world. Nearly 70% of donated blood comes from repeat or committed donors. The amount of iron removed in the 10 min or so it takes to withdraw a unit of blood (500 ml, plus 25 ml for testing) requires over 24 weeks to replace on a "standard" diet, i.e., without added iron in the form of supplements The cumulative effect of repeat blood donations without adequate iron replacement or a longer wait between donations results in iron deficiency (ID) in many donors, low haemoglobin deferral (~8% of donation attempts), and frank anaemia in some. Moreover, ID can be associated with side effects that can impact a blood donor's health, such as fatigue, cognitive changes and other neuromuscular symptoms. In an effort to better identify and prevent ID, blood collection agencies are recommending various strategies, including changes in the donation interval, donation frequency, testing of iron status and iron supplementation. In this review, we present the evidence basis for these strategies and suggest our own approaches to improving iron balance in blood donors.

show abstract

Dementia is associated with iron-deficiency anemia in females: A population-based study

Cited by 25 publications

References 32 publications

Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

History and progress of hypotheses and clinical trials for Alzheimer’s disease

How do we manage iron deficiency after blood donation?

Contact Info

Product

Resources

About